In this report we get into the details of aTyr pharma, going over the history of the company and disease as well as the discovery, pre-clin workup and clinical history of the drug, efzofitimod. I am short this name and think the drug effects observed in the ph1/2 are primarily due to a confounding baseline imbalance. The larger ph3 should not have this benefit and the drug effect should be too close to placebo to hit stat sig.
If only I had discovered this and sold at the time... Thank you very much for your detailed work!